re: Ann: IRD Confirms Viability of Sinter Fee... Waiting for an iron ore renaissance.
Sydney - Tuesday - November 22: (RWE Aust Business News) - Iron
Road (ASX:IRD) has positive results from sinter test work for the
proposed iron concentrate to be produced at the Central Eyre Iron Project
(CEIP) in South Australia.
It has confirmed the CEIP product will be suitable for use in
sinter plants as sinter feedstock and will not require additional
processing into pellets before use.
The available market for CEIP product is significantly larger
than many other proposed magnetite projects as the majority of blast
furnace based steel mills have associated sinter plants.
CEIP product will also avoid the possibility of future
constraints in pellet plant capacity.
Iron Road is now in a position to capture a premium price for
CEIP product, without incurring the added expense of additional
processing into pellets.
Sintering realises a cost benefit to final steel manufacture for
the proposed CEIP product, compared to typical magnetite concentrates
requiring pelletisation.
As a result, Iron Road is now confident that a premium above
Pilbara fines prices will be achieved for the 67pc iron content
concentrate, thus confirming a higher project value for CEIP.
Confirmation of the pricing premium will have positive
implications for project economics.
Sinter test work also shows possibility of CEIP product replacing
Australian and Brazilian fines in steel mill use.
The testing of CEIP 106um iron concentrate indicates coarse
particles contain the majority of the gangue material (feldspar and
quartz) and this fraction represents only 2.2pc of the product mass.
- Forums
- ASX - By Stock
- Ann: IRD Confirms Viability of Sinter Feed Produc
IRD
iron road limited
Add to My Watchlist
3.85%
!
2.5¢

re: Ann: IRD Confirms Viability of Sinter Fee... Waiting for an...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.5¢ |
Change
-0.001(3.85%) |
Mkt cap ! $20.71M |
Open | High | Low | Value | Volume |
2.7¢ | 2.7¢ | 2.2¢ | $19.75K | 828.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 90000 | 2.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 99999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 90000 | 0.023 |
2 | 177967 | 0.022 |
2 | 175000 | 0.021 |
3 | 621231 | 0.020 |
1 | 52684 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 99999 | 1 |
0.040 | 21966 | 1 |
0.042 | 15000 | 1 |
0.045 | 104450 | 2 |
0.060 | 67643 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
IRD (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online